The Role of Biomarkers in Ovarian Cancer Diagnostics

Biomarkers are essential for detecting ovarian cancer, monitoring disease progression, and guiding treatment decisions. CA-125 is the most commonly used biomarker, though it has limited sensitivity in early-stage ovarian cancer. HE4 complements CA-125 and improves diagnostic accuracy. The ROMA algorithm combines biomarker levels with menopausal status to assess malignancy risk.

Emerging biomarkers like OVX1, PAX2, and MMP7 show promise in enhancing early detection. Biomarker-based diagnostics are particularly valuable when combined with imaging and genetic testing, providing a comprehensive assessment of ovarian cancer risk and stage.

These innovations have increased adoption rates in developed regions, supported by government funding and private investment. Healthcare providers are emphasizing biomarker-based testing to ensure

personalized treatment and improved patient outcomes.

To explore the latest developments and market trends, see the Ovarian Cancer Diagnostics Market.